NYSE:ANVS Annovis Bio - ANVS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $15.25 +1.55 (+11.31%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$13.70▼$16.8150-Day Range$10.99▼$13.7052-Week Range$8.39▼$23.91Volume156,892 shsAverage Volume38,672 shsMarket Capitalization$124.50 millionP/E RatioN/ADividend YieldN/APrice Target$40.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Annovis Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside162.3% Upside$40.00 Price TargetShort InterestHealthy3.44% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.97) to ($2.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.89 out of 5 starsMedical Sector782nd out of 1,055 stocksPharmaceutical Preparations Industry389th out of 519 stocks 3.5 Analyst's Opinion Consensus RatingAnnovis Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.00, Annovis Bio has a forecasted upside of 162.3% from its current price of $15.25.Amount of Analyst CoverageAnnovis Bio has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.44% of the float of Annovis Bio has been sold short.Short Interest Ratio / Days to CoverAnnovis Bio has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Annovis Bio has recently decreased by 2.12%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAnnovis Bio does not currently pay a dividend.Dividend GrowthAnnovis Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANVS. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Annovis Bio this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for ANVS on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat Follows1 people have added Annovis Bio to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Annovis Bio insiders have not sold or bought any company stock.Percentage Held by Insiders39.50% of the stock of Annovis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.04% of the stock of Annovis Bio is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Annovis Bio are expected to grow in the coming year, from ($3.97) to ($2.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annovis Bio is -4.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annovis Bio is -4.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnnovis Bio has a P/B Ratio of 2.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Annovis Bio (NYSE:ANVS) StockAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.Read More Receive ANVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ANVS Stock News HeadlinesJanuary 27, 2023 | seekingalpha.comAnnovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drugJanuary 27, 2023 | seekingalpha.comAnnovis Bio begins phase 3 study of Buntanetap to treat Parkinson's diseaseJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 6, 2023 | finance.yahoo.comAnnovis Bio Announces New Appointments to Strengthen Its Senior Leadership TeamDecember 28, 2022 | ca.finance.yahoo.comAnnovis Bio, Inc. (ANVS)November 16, 2022 | finance.yahoo.comWall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 239%: Here's is How to TradeOctober 20, 2022 | finance.yahoo.comAnnovis Bio to Present at the 2022 ThinkEquity Investor ConferenceOctober 11, 2022 | finance.yahoo.comAnnovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's DiseaseJanuary 27, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…October 7, 2022 | finance.yahoo.comLab Notes: Venatorx lands federal contract that could be worth up to $318M; Annovis Bio receives FDA approval to proceed with trialOctober 6, 2022 | nasdaq.comAnnovis Bio Says FDA Authorizes Phase 2/3 Trial For Buntanetap In Alzheimer's DiseaseSeptember 13, 2022 | finance.yahoo.comAnnovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion DiseasesSeptember 12, 2022 | marketwatch.comAnnovis Bio Continues Gains With 29% IncreaseAugust 8, 2022 | finance.yahoo.comAnnovis Bio Announces Second Quarter 2022 Results and Provides Corporate UpdateJuly 14, 2022 | finance.yahoo.comAnnovis Bio to Present at the Alzheimer's Association International ConferenceJuly 7, 2022 | msn.comAnnovis Bio Gets FDA Nod For Late-Stage Parkinson Disease Study AmendmentsJuly 7, 2022 | investorplace.comAnnovis Bio (ANVS) Stock Soars 6% on Positive FDA UpdateJuly 7, 2022 | marketwatch.comAnnovis Bio Gets FDA Notice to Proceed With Buntanetap StudyJuly 7, 2022 | seekingalpha.comAnnovis Bio wins FDA nod to begin late-stage study for Parkinson's candidateJune 9, 2022 | finance.yahoo.comAnnovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by InfectionsMay 5, 2022 | seekingalpha.comAnnovis Bio reports Q1 resultsMay 2, 2022 | benzinga.comLadenburg Thalmann Initiates Coverage On Annovis Bio with Buy Rating, Announces Price Target of $37April 28, 2022 | finance.yahoo.comAnnovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on AgingMarch 23, 2022 | finance.yahoo.comAnnovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-VestMarch 21, 2022 | finance.yahoo.comDo Institutions Own Annovis Bio, Inc. (NYSE:ANVS) Shares?March 8, 2022 | finance.yahoo.comAnnovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022January 10, 2022 | finance.yahoo.comAnnovis Bio Enhances Leadership Team with Two Senior AppointmentsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ANVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ANVS Company Calendar Last Earnings11/08/2022Today1/27/2023Next Earnings (Estimated)3/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:ANVS CUSIPN/A CIK1477845 Webwww.annovisbio.com Phone610-727-3913FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Forecast$40.00 High Stock Price Forecast$40.00 Low Stock Price Forecast$40.00 Forecasted Upside/Downside+162.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-74.21% Return on Assets-71.12% Debt Debt-to-Equity RatioN/A Current Ratio12.86 Quick Ratio12.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.49 per share Price / Book2.78Miscellaneous Outstanding Shares8,164,000Free Float4,939,000Market Cap$124.50 million OptionableNot Optionable Beta1.22 Key ExecutivesDr. Maria L. Maccecchini Ph.D. (Age 71)Founder, CEO, Pres & Exec. Director Comp: $791.6kMr. Henry Hagopian III (Age 54)M.B.A., Chief Financial Officer Dr. Cheng Fang Ph.D.Sr. VP of R&DMs. Eve M. Damiano M.S.RAC, Sr. VP of Regulatory OperationsKey CompetitorsvTv TherapeuticsNASDAQ:VTVTAraviveNASDAQ:ARAVInflaRxNASDAQ:IFRXBeyondSpringNASDAQ:BYSIAtossa TherapeuticsNASDAQ:ATOSView All CompetitorsInsiders & InstitutionsMerit Financial Group LLCBought 23,150 shares on 1/13/2023Ownership: 0.529%Bank of New York Mellon CorpBought 8,837 shares on 12/8/2022Ownership: 0.421%BlackRock Inc.Sold 2,363 shares on 11/15/2022Ownership: 1.770%Bank of New York Mellon CorpBought 8,837 shares on 11/15/2022Ownership: 0.421%Two Sigma Advisers LPSold 6,200 shares on 11/15/2022Ownership: 0.145%View All Institutional Transactions ANVS Stock - Frequently Asked Questions Should I buy or sell Annovis Bio stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Annovis Bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANVS shares. View ANVS analyst ratings or view top-rated stocks. What is Annovis Bio's stock price forecast for 2023? 2 Wall Street analysts have issued 12 month price targets for Annovis Bio's shares. Their ANVS share price forecasts range from $40.00 to $40.00. On average, they predict the company's stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 192.0% from the stock's current price. View analysts price targets for ANVS or view top-rated stocks among Wall Street analysts. How have ANVS shares performed in 2023? Annovis Bio's stock was trading at $13.43 at the start of the year. Since then, ANVS stock has increased by 2.0% and is now trading at $13.70. View the best growth stocks for 2023 here. Are investors shorting Annovis Bio? Annovis Bio saw a increase in short interest during the month of December. As of December 30th, there was short interest totaling 198,300 shares, an increase of 21.9% from the December 15th total of 162,700 shares. Based on an average daily volume of 31,400 shares, the short-interest ratio is currently 6.3 days. Currently, 3.5% of the shares of the company are short sold. View Annovis Bio's Short Interest. When is Annovis Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023. View our ANVS earnings forecast. How were Annovis Bio's earnings last quarter? Annovis Bio, Inc. (NYSE:ANVS) issued its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.17) by $0.24. What other stocks do shareholders of Annovis Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Annovis Bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), KushCo (KSHB), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Auxly Cannabis Group (CBWTF), Novan (NOVN), Sorrento Therapeutics (SRNE), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF). When did Annovis Bio IPO? (ANVS) raised $10 million in an initial public offering on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) acted as the underwriter for the IPO. What is Annovis Bio's stock symbol? Annovis Bio trades on the New York Stock Exchange (NYSE) under the ticker symbol "ANVS." Who are Annovis Bio's major shareholders? Annovis Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Merit Financial Group LLC (0.53%). Insiders that own company stock include Claudine Bruck, Maria-Luisa Maccecchini and Reid Mccarthy. View institutional ownership trends. How do I buy shares of Annovis Bio? Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Annovis Bio's stock price today? One share of ANVS stock can currently be purchased for approximately $13.70. How much money does Annovis Bio make? Annovis Bio (NYSE:ANVS) has a market capitalization of $111.79 million. The company earns $-14,490,000.00 in net income (profit) each year or ($3.47) on an earnings per share basis. How can I contact Annovis Bio? Annovis Bio's mailing address is 1055 Westlakes Drive Suite 300, Berwyn PA, 19312. The official website for the company is www.annovisbio.com. The company can be reached via phone at 610-727-3913 or via email at joeh@gregoryfca.com. This page (NYSE:ANVS) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.